Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in IXI?

IXICO's contract wins reveal the business is gaining commercial traction

It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
mri scanner
The company's technology manages and helps interpret images from MRI and positron emission tomography as well as collating and making sense of biosensor data

A recent run of contract wins for IXICO Plc (LON:IXI) reveals a growing adoption of the digital technologies it uses to aid research in neuroscience.

Its platform manages and helps interpret images from MRI and positron emission tomography as well as collating and making sense of biosensor data.

WATCH: IXICO sees strong topline growth in interim results

The latest contract, for £1mln, will see IXICO provide its technology-enabled imaging services in a natural history study of people with early manifest Huntington's to observe the natural progression of the disease.

This is one of six areas in which it is actively supporting the hunt for breakthrough treatments, having landed contracts from companies active in Alzheimer’s, Parkinson’s, and multiple sclerosis.

Earlier this year a US$2.7mln deal with an unnamed global pharma company involved the use of IXICO’s TrialTracker digital platform and image analysis algorithms to collect and analyse MRI scans.

“Through our proven ability to collect and analyse clinical data in a standardised and regulatory-complaint format, we continue to build on our successful track record as a partner of choice to the biopharmaceutical industry,” said chief executive Giulio Cerroni.

Biogen collaboration 

But the IXICO business model far subtler than simply being a digital pharma services business.

Its collaboration with the giant Biogen is illustrative of this.

It is providing the brain scanning expertise that will allow physicians to monitor the effects of the company’s flagship product, Tysabri for multiple sclerosis.

While it is a hugely effective treatment, there is a risk of a serious side effect.

Certain patients are susceptible to the John Cunningham virus, which, once the immune system is suppressed, can affect the brain and ultimately result in serious harm or death.

IXICO’s technology helps spot the infection early, before it ever becomes a problem.

For Biogen this offers a huge boon – it is a way of keeping tabs on patients and it means more people can be safely put on the MS drug than are currently receiving it.

Crossing the Rubicon

In providing such a drug monitoring kit, IXICO has crossed the commercial Rubicon (if one can actually do that).

It has taken a useful piece of technology deployed in the clinical development of drugs and developed a companion product that will help doctors prescribe drugs more effectively.

Now, this is a hot area, one potentially worth tens of billions of pounds when it is fully developed and IXICO’s strategy is quite simple – it wants a small slither of the pie.

It is using the DNA from its current digital product, TrialTracker, and transplanted it into to new innovations.

First adopters

Remember, IXICO is already working with the likely first adopters of this technology – the major pharmaceuticals companies.

Its work to date means it has compiled and is augmenting the datasets required to excel in this field.

Why are the multi-national drug giants interested in companion products and willing to shell out for them?

Well, very soon these businesses may be paid on results.

The Biogen collaboration may be in its infancy, but it provides proof positive that IXICO’s strategy has legs.

Revenues rise 30%

Interim revenues to March climbed 30% to £2.9mln (£2.3mln).

At the end of the period, IXICO had £2.7mln of cash in the bank, which was topped up by an oversubscribed placing in May that raised £5.5mln.

At 33.5p, the AIM-listed company is valued at about £16mln.

View full IXI profile View Profile

IXICO Plc Timeline

May 14 2018
January 22 2018

Related Articles

cancer cells from taken by an electron microscope
March 13 2018
Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use